CAMBRIDGE, Mass., January 8, 2025 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation at the 43rd Annual JP Morgan Healthcare Conference, taking place January 13-16, 2025. Daniel Getts, Ph.D., CEO of Myeloid, will present on Wednesday, January 15, 2025, at 8:30 am PT. […]

CAMBRIDGE, Mass., November 13, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation at the Jefferies London Healthcare Conference, taking place November 19-21, 2024. Company management will participate in one-on-one meetings with investors and B2B meetings during the conference. About Myeloid Therapeutics Myeloid […]

CAMBRIDGE, Mass., August 29, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation in the following investor conferences: 22nd Annual Morgan Stanley Healthcare Conference, September 4-6, 2024, in New York, NY Wells Fargo Annual Healthcare Conference, September 4-6, 2024, in Boston, MA Chardan’s […]

CAMBRIDGE, Mass., August 1, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation in the Barclays Biotech: 1×1 Private Company Symposium on Wednesday, August 7, 2024. This event is being held in a virtual format during which Company management will participate in one-on-one […]

CAMBRIDGE, Mass, May 29, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, announced today that it will participate in the Jefferies Healthcare Conference Private Biotech Day, taking place June 4th, 2024, in New York. Company management will be conducting one-on-one meetings with investors at the conference. About Myeloid Therapeutics Myeloid Therapeutics is […]

CAMBRIDGE, Mass, April 15, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30. Daniel Getts, Ph.D., Chief Executive Officer of Myeloid, will participate in a fireside chat […]

Presented data support the ongoing clinical assessment of MT-302, the world’s first in vivo mRNA CAR drug development candidate Additional updates highlight Myeloid’s pioneering work, including a set of novel mRNA CAR constructs for in vivo programming of additional immune cell subsets, including NK and T cells CAMBRIDGE, Mass, April 4, 2024 – Myeloid Therapeutics, […]

CAMBRIDGE, Mass, March 5, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, at the San Diego Convention Center. Details follow: Title: In vivo programming […]

CAMBRIDGE, Mass, October 2, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences: Chardan’s 7th Annual Genetic Medicines Conference, taking place October 2-3, 2023, in NY Oppenheimer’s Private Company Symposium, taking place October 11, 2023, in NY 3rd Annual Needham Private Biotech […]

CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences: Citi’s 18th Annual BioPharma Conference, taking place September 5-7, 2023, in Boston, MA Management will participate in a fireside chat on September 6, 2023, at 11:20 am ET. […]